Epidermal DNA vaccine for influenza is immunogenic in humans
Epidermal DNA vaccine for influenza is immunogenic in humans
复制标题
DOI：
10.1016/j.vaccine.2005.08.012
复制
发表时间：
2006-05-22
期刊：
影响因子：
5.5
通讯作者：
Dean, Hansi J.
中科院分区：
文献类型：
--
作者：
Drape, Robert J.;Macklin, Michael D.;Dean, Hansi J.
进行I期临床试验以评估通过颗粒介导的表皮递送（PMED）递送的含有来自A/Panama/2007/99的HA基因的单价流感DNA疫苗。三组12名健康成年受试者在第0天接受1、2或4 μ g DNA疫苗的单剂量，作为1、2或4次PMED施用递送。PMED流感DNA疫苗在所有三个剂量水平下均引起血清血凝抑制（HAI）抗体应答，在接种最高剂量水平疫苗的受试者中应答最高且最一致。抗体应答在最后一个检测时间点（第56天）最大。给药相关反应为轻度至中度，包括疫苗接种部位的皮肤反应。这些结果提供了流感的原型表皮DNA疫苗的安全性和免疫原性的初步指示。(c)2005年爱思唯尔有限公司保留所有战斗。
A phase I clinical trial was conducted to evaluate a monovalent influenza DNA vaccine containing the HA gene from A/Panama/2007/99 delivered by particle-mediated epidermal delivery (PMED). Three groups of 12 healthy adult subjects received a single dose on day 0 of either 1, 2 or 4 mu g of DNA vaccine, delivered as 1, 2 or 4 PMED administrations. The PMED influenza DNA vaccine elicited serum hemagglutination-inhibition (HAI) antibody responses at all three dose levels, with the highest and most consistent responses in subjects vaccinated with the highest dose level. Antibody responses were greatest at the last time point tested, day 56. Treatment-related reactions were mild to moderate, and included skin reactions at the vaccine site. These results provide a preliminary indication of the safety and immunogenicity of a prototype epidermal DNA vaccine for influenza. (c) 2005 Elsevier Ltd. All fights reserved.